MCID: ART008
MIFTS: 40

Arteriosclerosis Obliterans

Categories: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

MalaCards integrated aliases for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 12 36 54 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5160
KEGG 36 H01626
MeSH 43 D001162
SNOMED-CT 67 361133006
UMLS 71 C0003851

Summaries for Arteriosclerosis Obliterans

KEGG : 36 Arteriosclerosis obliterans (ASO) is one of the most common peripheral vascular diseases that causes ischemic symptoms of the lower limbs. Symptoms include discomfort, numbness, intermittent claudication, or even gangrene and ulceration. The risk factors of ASO include age, male gender, smoking, hypertension, hyperlipidemia, diabetes mellitus, chronic renal failure, and hyperhomocysteinemia. There are no definitive treatments for ASO. The efficacy of surgical treatment is not satisfactory, and medication is required to maintain the postoperative vascular patency. In order to relieve symptoms such as cold sensation and intermittent claudication, drug therapy such as antiplatelet therapy and vasodilatory drugs are useful in the treatment of some patients with ASO. Adsorption of low-density lipoprotein (LDL) has also been applied for the treatment of ASO. At present, the diagnosis of ASO depends on several clinical tests, such as angiography, estimations of ankle/brachial index (ABI), and pulse-wave velocity (PWV), as well as the measurement of circulating hs-CRP levels. However, these examinations can only be detectable when ASO already developed, and there was no predictable markers for ASO in its earlier stages. Recent studies have reported that some micro RNAs could be serum markers for early-stage ASO.

MalaCards based summary : Arteriosclerosis Obliterans is related to peripheral vascular disease and coronary heart disease 1. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers and Adhesion. The drugs Aspirin and Remifentanil have been mentioned in the context of this disorder. Affiliated tissues include testes, bone and endothelial.

Wikipedia : 74 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

Related Diseases for Arteriosclerosis Obliterans

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 31.0 VCAM1 SELP IL6
2 coronary heart disease 1 30.9 VCAM1 SELP IL6 ADIPOQ
3 limb ischemia 30.6 MIR21 IL6 ICAM1 HGF
4 chronic venous insufficiency 30.5 VCAM1 SELP ICAM1
5 venous insufficiency 30.5 VCAM1 SELP ICAM1
6 vascular disease 30.5 VCAM1 SELP MIR21 IL6 ICAM1 ADIPOQ
7 lipoprotein quantitative trait locus 30.3 VCAM1 SELP MIR21 IL6 ICAM1
8 coronary stenosis 30.3 MIR21 IL6 ICAM1 ADIPOQ
9 carotid stenosis 30.3 VCAM1 SELP ICAM1 ADIPOQ
10 atherosclerosis susceptibility 30.2 VCAM1 SELP IL6 ICAM1 ADIPOQ
11 cerebrovascular disease 30.1 VCAM1 SELP MIR21 IL6 ICAM1 ADIPOQ
12 intermediate coronary syndrome 30.1 VCAM1 SELP MIR142 IL6
13 peripheral artery disease 30.0 VCAM1 SELP IL6 ICAM1 HGF
14 arteriosclerosis 29.8 VCAM1 SELP MIR21 MIR142 MIR133A1 IL6
15 heart disease 29.8 VCAM1 SELP MIR21 IL6 ICAM1 ADIPOQ
16 diabetes mellitus, type i 29.8 VCAM1 MIR21 IL6 ICAM1 ADIPOQ
17 systemic lupus erythematosus 29.0 VCAM1 SELP MIR21 MIR142 IL6 ICAM1
18 arteries, anomalies of 28.5 VCAM1 MIR22 MIR21 MIR142 MIR133A1 IL6
19 diabetes mellitus, noninsulin-dependent 28.2 VCAM1 SELP MIR21 MIR142 IL6 ICAM1
20 intermittent claudication 10.7
21 buerger disease 10.5
22 coronary artery aneurysm 10.5 VCAM1 ADIPOQ
23 obesity-hypoventilation syndrome 10.5 IL6 ADIPOQ
24 aortic aneurysm 10.4
25 hypercholesterolemia, familial, 1 10.4
26 aneurysm 10.4
27 actinic prurigo 10.4 VCAM1 ICAM1
28 rheumatoid vasculitis 10.4 VCAM1 ICAM1
29 hyperlipoproteinemia, type iii 10.3
30 macular degeneration, age-related, 9 10.3 VCAM1 SELP ICAM1
31 limbal stem cell deficiency 10.3 VCAM1 ICAM1
32 retinal vascular occlusion 10.3 SELP IL6 ICAM1
33 immune-complex glomerulonephritis 10.3 VCAM1 SELP ICAM1
34 shwartzman phenomenon 10.3 VCAM1 ICAM1
35 vein disease 10.3 SELP IL6 ICAM1
36 common cold 10.3 SELP IL6 ICAM1
37 leukostasis 10.3 VCAM1 IL6 ICAM1
38 aortic aneurysm, familial abdominal, 1 10.3
39 lipid metabolism disorder 10.3
40 end stage renal disease 10.3
41 diabetes mellitus 10.3
42 plasmodium vivax malaria 10.3 VCAM1 IL6 ICAM1
43 leukocyte adhesion deficiency, type i 10.3 VCAM1 SELP ICAM1
44 castleman disease 10.3 VCAM1 IL6 ICAM1
45 takayasu arteritis 10.2 VCAM1 IL6 ICAM1
46 sickle cell anemia 10.2 VCAM1 IL6 ICAM1
47 mooren's ulcer 10.2 VCAM1 ICAM1
48 hypertriglyceridemia, familial 10.2
49 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.2
50 ischemia 10.2

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to Arteriosclerosis Obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

Drugs & Therapeutics for Arteriosclerosis Obliterans

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Remifentanil Approved Phase 4 132875-61-7 60815
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
6
Probucol Approved, Investigational Phase 4 23288-49-5 4912
7 Hypnotics and Sedatives Phase 4
8 Narcotics Phase 4
9 Anesthetics, General Phase 4
10 Anesthetics Phase 4
11 Analgesics, Opioid Phase 4
12 Platelet Aggregation Inhibitors Phase 4
13 Analgesics Phase 4
14 Anesthetics, Intravenous Phase 4
15 Anesthetics, Inhalation Phase 4
16 Respiratory System Agents Phase 4
17 Anti-Asthmatic Agents Phase 4
18 Fibrinolytic Agents Phase 4
19 Phosphodiesterase Inhibitors Phase 4
20 Phosphodiesterase 3 Inhibitors Phase 4
21 Neuroprotective Agents Phase 4
22 Bronchodilator Agents Phase 4
23 Protective Agents Phase 4
24 Antioxidants Phase 4
25 Lipid Regulating Agents Phase 4
26 Hypolipidemic Agents Phase 4
27 Anticholesteremic Agents Phase 4
28 Antimetabolites Phase 4
29
Alprostadil Approved, Investigational Phase 2 745-65-3 149351 5280723
30 Vasodilator Agents Phase 2
31 Anticoagulants Phase 2
32
Heparin Approved, Investigational 9005-49-6 46507594 772
33 Mitogens
34 Endothelial Growth Factors
35 Calcium, Dietary
36 Anti-Bacterial Agents
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors
38 Antibiotics, Antitubercular
39 calcium heparin
40
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
3 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
4 Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities—A Phase II Multi-center Randomised Controlled Trial Unknown status NCT02877173 Phase 2 Alprostadil Liposomes for Injection;Alprostadil Injection
5 Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia Unknown status NCT02864654 Phase 1, Phase 2
6 Randomized Double Blind Placebo-Controlled Research Of Treatment Efficiency For Patients With Lower Extremity Arteriosclerosis Obliterans By Autologous Transplantation Of Bone Marrow Progenitor Cells Completed NCT00753025 Phase 2
7 A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD) Recruiting NCT02501018 Phase 2 SOC
8 Recombinant SeV-hFGF2 / dF Injection (BF30) Single-dose Therapy in Patients With Peripheral Arterial Occlusive Disease, a Dose Escalation, Safety, Tolerability Phase I Clinical Trial Recruiting NCT03668353 Phase 1
9 Therapeutic Angiogenesis Using Cell Transplantation (TACT) Study at Nagoya Unknown status NCT00145262
10 Peripheral Blood Autologous CD34+ Cell Transplantation Promotes Angiogenesis in Elderly Patients With Atherosclerotic Ischemia: Study Protocol for a Prospective, Single-center, Open-label, Randomized, Controlled, Clinical Trial Unknown status NCT03098771 the control group
11 Study of the Mechanisms of the Arterial Calcification of the Members Subordinates in the Diabetes (Implication of the System RANK / RANKL / OSTEOPROTEGERINE) Unknown status NCT02431234
12 Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep Stages Completed NCT00712946
13 Epidemiology of Atherosclerosis Completed NCT00005147
14 HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F): a RCTrial to Evaluate the Effect of LDL-apheresis on the Recovery of Diabetic Ulcers in Patients With Peripheral Vasculopathy Not Susceptible to Revascularization. Completed NCT01518205

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Tolazoline
Tolazoline Hydrochloride

Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

Anatomical Context for Arteriosclerosis Obliterans

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

40
Testes, Bone, Endothelial, Heart, Bone Marrow, Smooth Muscle, Skin

Publications for Arteriosclerosis Obliterans

Articles related to Arteriosclerosis Obliterans:

(show top 50) (show all 1016)
# Title Authors PMID Year
1
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. 61 54
19225945 2009
2
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. 54 61
17126824 2007
3
Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. 54 61
15238569 2004
4
A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. 61 54
12882890 2003
5
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. 61 54
11505083 2001
6
[A new medical treatment for thrombosis by genetic engineering]. 54 61
10429451 1999
7
Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. 61 54
10373220 1999
8
[Blood coagulation disorders observed in arteriosclerosis obliterans]. 61 54
8808808 1996
9
Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report. 61
32306290 2020
10
Effects of Valsartan on Restenosis in Patients with Arteriosclerosis Obliterans of the Lower Extremities Undergoing Interventional Therapy: A Prospective, Randomized, Single-Blind Trial. 61
32541643 2020
11
Predictors of fatal outcome after severe necrotizing fasciitis: Retrospective analysis in a tertiary hospital for 20 years. 61
32414564 2020
12
Preoperative sepsis is a predictive factor for 30-day mortality after major lower limb amputation among patients with arteriosclerosis obliterans and diabetes. 61
31227298 2020
13
TIM‑3 inhibits PDGF‑BB‑induced atherogenic responses in human artery vascular smooth muscle cells. 61
32467985 2020
14
Midterm Outcome of Directional Atherectomy Combined with Drug-Coated Balloon Angioplasty Versus Drug-Coated Balloon Angioplasty Alone for Femoropopliteal Arteriosclerosis Obliterans. 61
31449956 2020
15
Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Predict Severity and Prognosis of Lower Limb Arteriosclerosis Obliterans. 61
31655109 2020
16
Establishment of optimal exercise therapy using near-infrared spectroscopy monitoring of tissue muscle oxygenation after therapeutic angiogenesis for patients with critical limb ischemia: A multicenter, randomized, controlled trial. 61
32072074 2020
17
Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-derived Mononuclear Cell Implantation in Patients with No-option Critical Limb Ischemia. 61
32273917 2020
18
Analysis of Risk Factors for Bronchopleural Fistula after Surgical Treatment of Lung Cancer. 61
32224595 2020
19
A case of ischemic osteopathy in a hemodialysis patient with advanced peripheral artery disease. 61
31637589 2020
20
Expression and clinical significance of HSP27 and its phosphorylation in lower extremity arteriosclerosis obliterans. 61
32566403 2020
21
Endothelin-1 and C Reactive Protein as Potential Biomarkers for Restenosis in Patients with Arteriosclerosis Obliterans. 61
32000546 2020
22
Clinical Significance of Endothelin-1 And C Reaction Protein in Restenosis After the Intervention of Lower Extremity Arteriosclerosis Obliterans. 61
31996054 2020
23
miR-21 regulates vascular smooth muscle cell function in arteriosclerosis obliterans of lower extremities through AKT and ERK1/2 pathways. 61
31749878 2019
24
Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4/NF-κB signaling pathway. 61
31410117 2019
25
MiR-126 promotes endothelial cell apoptosis by targeting PI3K/Akt in rats with lower limb arteriosclerosis obliterans. 61
31389593 2019
26
MiR-210 inhibits apoptosis of vascular endothelial cells via JAK-STAT in arteriosclerosis obliterans. 61
31389592 2019
27
Evaluation of Risk Factors for Limb-Specific Peripheral Vascular Events in Patients With Peripheral Artery Disease: A Post Hoc Analysis of the SEASON Prospective Observational Study. 61
30477334 2019
28
The Association of Cardio-Ankle Vascular Index and Ankle-Brachial Index with Macroangiopathy in Patients with Type 2 Diabetes Mellitus. 61
30487347 2019
29
Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity. 61
31086577 2019
30
Efficacy of trimetazidine and plasmin combined with alprostadil in treatment of lower extremity arteriosclerosis obliterans. 61
31086587 2019
31
Effect of lncRNA H19 on the apoptosis of vascular endothelial cells in arteriosclerosis obliterans via the NF-κB pathway. 61
31173326 2019
32
[Femoral-popliteal Arteriosclerosis Obliterans:Review of Evidence-based Studies on Drug-eluting Endovascular Treatment]. 61
31060683 2019
33
Analysis of finger vein variety in patients with various diseases using vein authentication technology. 61
30565416 2019
34
Hospital Discharge Teaching for Patients with Peripheral Vascular Disease. 61
30736938 2019
35
A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis. 61
30446942 2019
36
Evaluation of serum adiponectin levels in diabetic nephropathy. 61
30641684 2019
37
miR-29a Regulates the Proliferation and Migration of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans of the Lower Extremities. 61
31614351 2019
38
[Application of femoral-femoral artery bypass grafting combined with transverse tibial bone transporting for lower extremity arteriosclerosis obliterans or combined with diabetic foot]. 61
30569686 2018
39
First-in-Man Clinical Pilot Study Showing the Safety and Efficacy of Intramuscular Injection of Basic Fibroblast Growth Factor With Atelocollagen Solution for Critical Limb Ischemia. 61
30416190 2018
40
[Well Leg Compartment Syndrome after Cystectomy in the Lithotomy Position: A Case Report]. 61
30831665 2018
41
A case of ischemic gastroduodenal disease in a patient who was receiving hemodialysis treatment that was managed by conservative treatment. 61
29737481 2018
42
2015 JAPAN Critical Limb Ischemia Database (JCLIMB) Annual Report. 61
30402196 2018
43
Outcomes in Patients with Critical Limb Ischemia due to Arteriosclerosis Obliterans Who Did Not Undergo Arterial Reconstruction. 61
30101855 2018
44
[Warming needling combined with Zhuyu Tongluo Xuebi decoction for arteriosclerosis obliterans with stasis]. 61
30141289 2018
45
Outcome From a Randomized Controlled Clinical Trial - Improvement of Peripheral Arterial Disease by Granulocyte Colony-Stimulating Factor-Mobilized Autologous Peripheral-Blood-Mononuclear Cell Transplantation (IMPACT). 61
29877199 2018
46
Increased plasma olfactomedin 2 after interventional therapy is a predictor for restenosis in lower extremity arteriosclerosis obliterans patients. 61
29553861 2018
47
[Panax notoginseng extract combined with alprostadil in treatment of arteriosclerosis obliterans: Meta-analysis]. 61
29751719 2018
48
Evaluation of paramalleolar and inframalleolar bypasses in dialysis- and nondialysis-dependent patients with critical limb ischemia. 61
28965798 2018
49
Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan. 61
29386474 2018
50
Membranoproliferative glomerulonephritis with unusual deposits of parallel arrangement striated structure: a new pathological entity?
. 61
29057733 2018

Variations for Arteriosclerosis Obliterans

Expression for Arteriosclerosis Obliterans

Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for Arteriosclerosis Obliterans

GO Terms for Arteriosclerosis Obliterans

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 VCAM1 SELP MIR22 MIR21 MIR142 MIR133A1
2 platelet dense granule membrane GO:0031088 8.96 SELP CD63

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.86 VCAM1 IL6 ICAM1 HGF
2 platelet degranulation GO:0002576 9.74 SELP HGF CD63
3 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 SELP MIR21 HGF
4 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.7 MIR21 MIR133A1 ADIPOQ
5 positive regulation of osteoblast differentiation GO:0045669 9.65 MIR21 IL6 HGF
6 negative regulation of cell migration GO:0030336 9.62 TPM1 MIR21 MIR133A1 ADIPOQ
7 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.61 VCAM1 SELP ICAM1
8 leukocyte tethering or rolling GO:0050901 9.58 VCAM1 SELP
9 negative regulation of cardiac muscle hypertrophy GO:0010614 9.58 MIR21 MIR133A1
10 positive regulation of neuroinflammatory response GO:0150078 9.55 MIR142 IL6
11 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.54 TPM1 MIR133A1 ADIPOQ
12 positive regulation of smooth muscle cell differentiation GO:0051152 9.51 OLFM2 MIR22
13 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.49 MIR21 IL6
14 membrane to membrane docking GO:0022614 9.46 VCAM1 ICAM1
15 leukocyte cell-cell adhesion GO:0007159 9.43 VCAM1 SELP ICAM1
16 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.4 MIR21 HGF
17 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.33 TPM1 MIR21 ADIPOQ
18 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.26 IL6 ICAM1 HGF ADIPOQ
19 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 8.8 MIR21 IL6 ICAM1

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR22 MIR21 MIR142 MIR133A1

Sources for Arteriosclerosis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....